Evaluating lung patterns in patients with systemic sclerosis
Unsupervised Clustering Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Central Hospital, Nancy, France · NCT05482607
This study is trying to see if looking at lung scans can help doctors better understand and manage lung problems in patients with systemic sclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France (other) |
| Locations | 1 site (Nancy) |
| Trial ID | NCT05482607 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with systemic sclerosis (SSc) who also have interstitial lung disease (ILD). It aims to classify the variability of SSc-ILD by analyzing high-resolution computed tomography (HRCT) scans to identify distinct radiological patterns. The study employs unsupervised clustering analysis to categorize these patterns, which may help in understanding the disease's progression and prognosis. By examining the relationship between HRCT findings and clinical outcomes, the study seeks to enhance patient management strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with systemic sclerosis who exhibit interstitial lung disease as confirmed by HRCT scans.
Not a fit: Patients with alternative diagnoses of SSc-associated ILD, such as silicosis, sarcoidosis, or lung cancer, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved classification and management of interstitial lung disease in systemic sclerosis patients, potentially enhancing patient outcomes.
How similar studies have performed: While the approach of using HRCT patterns in systemic sclerosis is not widely tested, similar studies in other interstitial lung diseases have shown promise in improving patient classification and management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with systemic sclerosis according to 2013 ACR/EULAR criteria * Patients with interstitial lung disease on HRCT chest Exclusion Criteria: * Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)
Where this trial is running
Nancy
- Central Hospital — Nancy, France (RECRUITING)
Study contacts
- Principal investigator: Paul Decker, MD — Central Hospital, Nancy, France
- Study coordinator: Paul DECKER, MD
- Email: p.decker@chru-nancy.fr
- Phone: +33383157240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Systemic Sclerosis, Interstitial Lung Disease